Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The report focuses on investment opportunities in the dual-antibody treatments in the autoimmune sector, highlighting the unmet needs in existing therapies and the potential for blockbuster drugs [5][15] - The report emphasizes the long-term trends in innovative drugs, the recovery of the CRO industry, and the potential for growth in various sub-sectors of the pharmaceutical industry [8][22][28] Summary by Relevant Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 9157.77, with a 52-week high of 9323.49 and a low of 6070.89 [2] Recent Market Performance - During the week of September 8 to September 12, 2025, the A-share pharmaceutical and biotechnology sector fell by 0.36%, underperforming the CSI 300 index by 1.75 percentage points and the ChiNext index by 2.47 percentage points [7][19][36] Investment Recommendations 1. **Innovative Drugs**: The report suggests that domestic innovative drugs are poised for global competition, with significant potential for growth in the oncology and respiratory sectors. Beneficiaries include companies like Innovent Biologics and Junshi Biosciences [8][22] 2. **CRO Sector**: The report indicates that the CRO industry is expected to see a recovery in profitability due to stable competition and increasing demand from innovative drug development [22][24] 3. **Biological Products**: Focus on core product volume opportunities and potential valuation re-evaluations based on product data or business development expectations. Key companies include TianTan Bio and Anke Bio [9][28] 4. **Medical Devices**: The report anticipates a turning point in the medical device sector due to improved procurement processes and funding availability [29] 5. **Traditional Chinese Medicine**: The report highlights opportunities in innovative research and policies benefiting traditional Chinese medicine companies [32][34] Market Trends - The report notes that the overall valuation of the pharmaceutical sector (TTM) is 31.72, with a relative valuation premium of 136.86% over the CSI 300 index, indicating a slight decrease from the previous week [42]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [6] Core Insights - The report highlights the promising clinical data of BaiLi Tianheng's EGFR/HER3 dual antibody ADC, iza-bren, for treating EGFR mutation lung cancer, which shows potential for further clinical advancement [2][3][20][21][23] Summary by Sections Weekly New Drug Market Review - From September 8 to September 14, 2025, the top five gainers in the new drug sector were: - Saintno Pharmaceutical (+32.00%) - Junshengtai (+23.73%) - Canaan Bio (+20.43%) - Rongchang Bio (+16.52%) - Hengrui Medicine (+11.91%) - The top five losers were: - Basestone Pharmaceuticals (-18.90%) - Laika Pharmaceuticals (-18.12%) - Gilead Sciences (-16.93%) - Maiwei Bio (-14.41%) - Yifang Bio (-12.46%) [1][15] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences, business development realizations, and insurance negotiations. Key stocks to watch include: 1. Potential overseas licensed MNC heavyweights: - Differentiated GLP-1 assets: Zhongsheng Pharmaceutical, Gilead Sciences, Borui Pharmaceutical, Kangyuan Pharmaceutical - Upgraded PD-1 products: Kangfang Bio and other PD-1/VEGF assets, Innovent Biologics - Breakthroughs in autoimmune fields: Yifang Bio, China Antibody - Innovative target ADCs: Fuhong Hanlin, Shiyao Group 2. MNC-certified products with high overseas volume certainty: - Upgraded PD-1 products: Sanofi Pharmaceutical - GLP-1 assets: Lianbang Pharmaceutical - ADC assets: Kelong Botai, BaiLi Tianheng 3. Products likely to benefit from insurance negotiations and innovative drug directories [2][20] New Drug Industry Focus Analysis - At the recent 2025 World Lung Cancer Conference (WCLC), BaiLi Tianheng presented results from two studies on its EGFR×HER3 dual antibody ADC, iza-bren, showing excellent clinical data in both first-line and second-line treatments for advanced or metastatic EGFR mutation NSCLC. The results indicate a promising future for its application in relevant indications [2][20][21] New Drug Approval and Acceptance Status - No new drug or new indication applications were approved this week, but seven new drug or new indication applications were accepted [3][25] Clinical Application Approval and Acceptance Status - This week, 41 new drug clinical applications were approved, and 46 new drug clinical applications were accepted [9][28]

Core Insights - Complement drugs are specifically designed to treat diseases related to abnormal activation or suppression of the complement system, with a complex development history that faced significant challenges until the first drug, Soliris, was approved in 2007 [1][4] - The market for complement drugs is expanding rapidly, with a projected global market size of $8.179 billion in 2024, reflecting a year-on-year growth of 23.4%, primarily driven by advancements in treatment for eye diseases [1][6] - The leading complement drugs in the market are AstraZeneca's C5 antibodies, Soliris and Ultomiris, which together are expected to account for 79.6% of total sales in 2024 [1][6][7] Industry Overview - The complement drug industry has evolved to include over ten approved drugs, utilizing various forms such as monoclonal antibodies, small molecule inhibitors, cyclic peptides, and nucleic acid aptamers, indicating a diverse technological landscape [1][4] - The expansion of indications from rare blood diseases to more common conditions signifies a maturation in the development of complement drugs, with ongoing research opening new therapeutic areas [1][4][8] Market Dynamics - The sales of Ultomiris are projected to grow significantly, from $339 million in 2019 to $3.924 billion in 2024, surpassing Soliris, which is expected to see a decline in sales by 17.7% to $2.588 billion in 2024 [7] - Domestic companies such as Heng Rui Medicine and Hai Si Ke are actively entering the complement drug market, with over ten clinical trials registered in China, primarily focusing on IgA nephropathy [1][8] Future Trends - The competition in the complement drug market is expected to intensify with the introduction of more drugs, emphasizing technological innovation and cost reduction to enhance accessibility [8] - There is a growing focus on multi-target and combination therapy strategies, which may improve treatment efficacy and reduce side effects, as well as an expansion of applications to include more rare and autoimmune diseases [8]

Core Viewpoint - The pharmaceutical industry is experiencing structural differentiation, with the innovative drug sector (Biotech) emerging as a significant growth driver, showcasing a revenue increase of 14.12% in the first half of 2025, particularly a remarkable 44.63% growth in Q2 [1][4]. Industry Overview - The overall pharmaceutical industry reported a slight revenue decline of 1.15% in Q2 2025, but net profit showed a positive growth of 0.79% [1]. - Despite challenges such as centralized procurement and external disruptions, there are signs of performance recovery driven by policy optimization, commercial insurance expansion, and AI empowerment [1][2]. Financial Performance - The Biotech sector's revenue growth in H1 2025 was 14.1%, with Q2 alone achieving a growth rate of 44.6% [6]. - The gross profit margin for the Biotech sector was 85.0%, indicating a narrowing of losses and a shift towards profitability [6]. - The sales expense ratio increased, but management and R&D expense ratios decreased, reflecting cost control and efficiency improvements [6]. Growth Drivers - The growth in innovative drugs is attributed to the launch of effective and safe new drugs, supportive national policies, and significant revenue from licensing agreements [4][6]. - The average transaction amounts for licensing agreements in 2025 have reached global averages, indicating a robust international market for Chinese innovative drugs [9][11]. Market Trends - The innovative drug sector is transitioning from a "burning cash" phase to a "profit-making" phase, with several companies reporting net profits for the first time [6][14]. - The number of significant licensing deals has surged, with China accounting for over 25% of global heavy-weight transactions in 2025 [11][13]. Investment Opportunities - The innovative drug sector is entering a harvest phase, with expectations for further growth driven by upcoming clinical data and favorable economic conditions [14]. - Investors are encouraged to consider diversified investment products, such as ETFs, to mitigate risks associated with individual stock selection in the innovative drug space [14][16].

Core Insights - The article highlights the changes in the Hong Kong Stock Connect holdings, with notable increases in ownership for certain companies and decreases for others [1][2]. Group 1: Companies with Increased Holdings - Changfei Fiber Optics (06869) saw an increase of 2.14%, bringing its latest holding ratio to 59.98% [2]. - Shandong Gold (01787) experienced a 1.80% increase, with a new holding ratio of 58.88% [2]. - Haotian International Construction Investment (01341) had a 1.51% increase, resulting in a holding ratio of 57.62% [2]. - Over the last five trading days, Shandong Gold (01787) had the highest increase at 6.06%, with a holding ratio of 58.88% [3]. - Changfei Fiber Optics (06869) also increased by 5.95%, reaching a holding ratio of 59.98% [3]. - Yimai Sunshine (02522) saw a 5.52% increase, with a holding ratio of 43.15% [3]. Group 2: Companies with Decreased Holdings - Spring Medical (01858) experienced the largest decrease at -2.53%, with a holding ratio of 44.43% [2]. - BRILLIANCE CHI (01114) saw a reduction of -1.61%, resulting in a holding ratio of 14.02% [2]. - ZTE Corporation (00763) had a decrease of -1.37%, with a holding ratio of 51.54% [2]. - Over the last five trading days, Heng Seng China Enterprises (02828) had the largest decrease at -13.70%, with a holding ratio of 2.71% [3]. - Hong Kong Broadband (01310) decreased by -9.74%, reaching a holding ratio of 0.27% [3]. - The Yingfu Fund (02800) saw a reduction of -4.75%, with a holding ratio of 3.33% [3]. Group 3: Notable Trends - The article provides a detailed list of the top 20 companies with the largest increases and decreases in holdings, indicating significant shifts in investor sentiment [2][3]. - The data reflects a dynamic trading environment, with certain companies gaining traction while others are losing investor interest [1][2].

Group 1 - The pharmaceutical sector has regained momentum, with A-shares in innovative drugs showing strong recovery, particularly the drug ETF (562050) which surged by 3.36%, reaching a record closing high [1] - The Hong Kong stock market saw even greater gains in innovative drugs, with the Hong Kong Stock Connect innovative drug ETF (520880) rising by 4.52%, also hitting a new closing high [1][3] - The innovative drug ETF (520880) currently covers 29 innovative drug concept stocks, all of which have shown positive performance, with notable increases in stocks like Sanofi and Kintor Pharmaceutical [3] Group 2 - The innovative drug ETF (520880) has achieved an impressive year-to-date increase of 118.95%, leading among similar indices [3] - A significant index revision will take effect on September 8, 2023, which will exclude CXO companies, focusing solely on innovative drug R&D firms, enhancing the ETF's purity [3] - The Hang Seng Innovative Drug Select Index has shown varying annual performance since its inception, with a notable decline in previous years, but the current market sentiment suggests a potential upward trend [5] Group 3 - Upcoming major conferences, including the World Lung Cancer Conference and the European Oncology Congress, are expected to catalyze further developments in the innovative drug sector [5] - The medical ETF has a total scale of 263.25 billion yuan, making it the largest medical ETF in the market [5]

Group 1 - The pharmaceutical sector has regained momentum, with A-shares in innovative drugs showing strong recovery, particularly the drug ETF (562050) which surged by 3.36%, reaching a record closing high [1] - The Hong Kong stock market saw even greater gains in innovative drugs, with the Hong Kong Stock Connect innovative drug ETF (520880) rising by 4.52%, also hitting a new closing high [1][3] - The innovative drug ETF (520880) currently covers 29 innovative drug concept stocks, all of which have shown positive performance, with notable increases in stocks like Sanofi and Kintor Pharmaceuticals [3] Group 2 - The innovative drug ETF (520880) will undergo a "purification" revision on September 8, 2023, removing CXO companies and focusing solely on innovative drug R&D firms, thus becoming a 100% pure innovative drug index [3] - As of September 3, 2023, the cumulative year-to-date increase for the index tracked by the innovative drug ETF (520880) reached 118.95%, leading among similar indices [3][4] - The Hang Seng Innovative Drug Select Index has shown significant fluctuations in past years, with a notable increase in 2023, indicating a potential upward trend in the innovative drug sector [5] Group 3 - Upcoming key academic conferences, including the World Lung Cancer Conference and the European Oncology Congress, are expected to catalyze further developments in the innovative drug sector [5] - The medical ETF has a total scale of 26.325 billion yuan, making it the largest medical ETF in the market [5]

Market Overview - The Hong Kong stock market rebounded strongly, with the Hang Seng Index rising 1.43% to close at 25,417.98 points, and a total trading volume of 299.945 billion HKD [1] - The Hang Seng Tech Index increased by 1.95%, while the Hang Seng China Enterprises Index rose by 1.34% [1] - The overall weekly performance showed a cumulative increase of 1.36% for the Hang Seng Index [1] Foreign Investment Trends - The Cathay Pacific Haitong overseas strategy team indicated that under the backdrop of the Federal Reserve potentially restarting interest rate cuts, there is a possibility of unexpected foreign capital inflow into the Hong Kong stock market [1] - Foreign investment in Hong Kong stocks is particularly favoring technology and financial sectors [1] Sector Performance Blue-Chip Stocks - Xinyi Solar (00968) led blue-chip stocks with a 7.54% increase, closing at 3.71 HKD, contributing 1.89 points to the Hang Seng Index [2] - Other notable performers included China Biologic Products (01177) up 6.2% and Hang Lung Properties (00101) up 6.13% [2] New Energy Sector - The new energy sector, including solar and energy storage, saw significant gains, with companies like China Innovation Aviation (03931) rising 18.37% and New Special Energy (01799) up 17.28% [3][4] - The Ministry of Industry and Information Technology's recent action plan aims to guide the orderly layout of the photovoltaic and lithium battery industries, indicating potential for industry recovery [3][4] Innovative Pharmaceuticals - The innovative drug sector rebounded, with companies like Three-San Pharmaceutical (01530) increasing by 18.24% [4] - The upcoming World Lung Cancer Conference (WCLC) is expected to showcase significant contributions from Chinese scholars, highlighting the growth in the pharmaceutical sector [5] Gold Stocks - Gold stocks collectively rose, with Shandong Gold (01787) increasing by 5.87% [5] - The market anticipates a continued rise in gold prices, driven by high demand and traditional consumption peaks [5] Employment Data Impact - Recent ADP data indicated an increase of 54,000 jobs in the U.S. for August, which was below market expectations, reinforcing the likelihood of interest rate cuts by the Federal Reserve [6] - The market is closely watching the upcoming U.S. non-farm payroll data for further insights [6] Chip Sector Recovery - The semiconductor sector saw a rebound, with notable increases in stocks like Innodisk (02577) up 8.52% and SMIC (00981) up 4.82% [6][7] - The Ministry of Industry and Information Technology's action plan emphasizes support for AI chips and other critical technologies, indicating a focus on domestic production and innovation [7] Notable Stock Movements - Tianyue Advanced (02631) reached a new high, closing up 18.24% [8] - Goldwind Technology (02208) reported a 41.46% year-on-year revenue increase, reflecting strong market performance [9] - Chow Tai Fook (06168) surged 16.58% amid rising gold prices and seasonal demand [10] - Huya Technology (01860) saw a 9% increase, driven by significant revenue growth attributed to AI-driven systems [11] - Zhongshen Construction (02503) experienced a drastic decline of 72.36% following a poor financial report [12]

Core Viewpoint - The Hong Kong stock market experienced a significant rally, with the Hang Seng Index rising over 1% and the Hang Seng Tech Index increasing by more than 2% [1] Market Performance - The pharmaceutical sector continued to lead the market, with the Hang Seng Pharmaceutical ETF (159892) surging over 4% in the afternoon session [1] - The CXO-focused medical ETF (520510) also saw an increase of over 3% [1] - Notable stocks included 3SBio, which rose by nearly 16%, along with ConvaTec, Crystal Technology, and Xiansheng Pharmaceutical leading the gains [1] Upcoming Events - The 2025 World Lung Cancer Conference (WCLC) is scheduled to take place from September 6 to September 9 in Barcelona, Spain [1] - Several leading innovative drug companies are expected to unveil significant new products during the conference, which will provide new development opportunities and market attention for innovative drug enterprises [1]

Group 1 - The Hong Kong innovative drug sector experienced significant gains, with companies such as Sangfor Biopharma, Eucure Biopharma, and CanSino Biologics rising by 16%, 13%, and 12% respectively, leading to a 4.54% increase in the Hang Seng Innovative Drug ETF (159316) [1] - The World Lung Cancer Conference (WCLC) is scheduled from September 6 to 9, where Chinese pharmaceutical companies such as CanSino Biologics, BeiGene, Junshi Biosciences, and Bairui Tianheng will present their latest research advancements [1] - The trend of Chinese innovative drugs going global is becoming normalized, with the amount of License out (patent authorization abroad) reaching nearly $80 billion from January to July, a year-on-year increase of over 160% [1] Group 2 - Recent U.S. employment data supports a potential interest rate cut in September, which could lead to a favorable investment environment and new breakthroughs in the global innovative drug industry, benefiting Chinese innovative drugs [1] - The Hang Seng Innovative Drug ETF (159316) is the only ETF tracking the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which has been updated to exclude CXO, making it a 100% "pure" innovative drug index that accurately reflects the overall performance of Chinese innovative pharmaceutical companies [1] - The ETF has attracted significant capital inflow, with a total of 290 million yuan in the past five days and over 1.6 billion yuan in the last 60 days [1]